ASND stock forecast, quote, news & analysis
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients... Show more
Why Ascendis Pharma (ASND) Stock Is Down -10% in the Last 30 Days
Key Takeaways
- Ascendis Pharma (ASND) shares declined approximately 10% over the past 30 days, falling from $277.18 on July 8, 2026, to around $249.43 as of early August — largely driven by profit-taking after a sharp rally in late June tied to Russell index inclusion.
- Over the broader quarter, ASND has been essentially flat, masking significant intra-quarter volatility that included a dip below $204 in early June and a surge above $274 in early July.
- The company reported Q2 2026 earnings on August 6 after market close; early after-hours trading suggested a modestly positive reception, with the stock recovering from its July lows.
- Key fundamental drivers — including robust YORVIPATH patient growth, the U.S. launch of YUVIWEL, and a strengthening balance sheet — remain intact despite the recent pullback.
- Biotech sector rotation, macroeconomic uncertainty, and profit-booking following the Russell reconstitution rally were the primary forces behind the 30-day decline.
Ascendis Pharma (ASND) Company Overview and Market Position
Ascendis Pharma A/S is a Denmark-based global biopharmaceutical company specializing in rare endocrine diseases. The company's proprietary TransCon technology platform enables the development of long-acting prodrug therapies that deliver sustained drug exposure with reduced dosing frequency. Ascendis currently markets three FDA-approved products: YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism in adults, SKYTROFA (lonapegsomatropin) for pediatric and adult growth hormone deficiency, and YUVIWEL (navepegritide), which received accelerated FDA approval in February 2026 for pediatric achondroplasia and launched commercially in April 2026. Headquartered in Copenhagen with operations across Europe and the United States, Ascendis competes in the rare disease space against companies such as BioMarin Pharmaceutical and has attracted strong institutional support, with a consensus "Strong Buy" rating from Wall Street analysts.
Ascendis Pharma (ASND) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 calendar days, ASND shares declined from a closing price of $277.18 on July 8, 2026, to an intraday price of approximately $249.43 on August 6, representing a drop of roughly 10%. The decline was characterized by a steady downward trend through most of July, punctuated by a session low near $239.56 on August 4 before a modest recovery in the final trading days of the period. The move erased a significant portion of the gains accumulated during the late-June rally that pushed shares above $274.
Zooming out to the last quarter, the stock's trajectory has been far more turbulent. ASND closed at $246.14 on May 7, 2026, immediately following its Q1 earnings report. From there, shares tumbled to as low as $203.80 on June 8 amid a broader biotech sell-off, before staging a dramatic recovery that culminated in a closing high of $274.50 on July 2 — a gain of roughly 35% from the June trough. The subsequent 30-day pullback brought shares nearly back to the early-May starting point, underscoring the stock's high-beta character and sensitivity to both sector-wide flows and company-specific catalysts.
What Drove ASND Stock Price in the Last 30 Days
The approximately 10% decline in ASND shares over the past 30 days was driven primarily by technical and sentiment-based factors rather than deterioration in the company's fundamental outlook. The single largest catalyst for the pullback was profit-taking following the extraordinary rally triggered by Ascendis Pharma's inclusion in multiple Russell U.S. indexes — including the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap — effective June 26, 2026. The reconstitution event drove heavy institutional buying, with shares surging from $238.01 on June 24 to $261.58 on June 25, and continuing higher into early July. Once index-related demand subsided, traders and funds moved to lock in gains, initiating a multi-week unwinding that defined the stock's July price action.
Additional headwinds included a broader rotation away from high-growth biotech names amid renewed macroeconomic uncertainty and a risk-off tilt in equity markets during the second half of July. The company's Q2 2026 earnings report, released after the market close on August 6, served as a potential inflection point — the stock showed early signs of stabilization heading into the print, and preliminary after-hours trading suggested a constructive market response. Separately, Ascendis presented long-term clinical data at ENDO 2026 in mid-June, including five-year results from the Phase 2 PaTH Forward trial confirming sustained efficacy and safety of TransCon PTH, which reinforced the long-term investment thesis but did not prevent near-term selling pressure.
What Drove ASND Stock Performance Over the Last Quarter
The last quarter was defined by a "V-shaped" pattern for ASND shares. The early-May Q1 2026 earnings report delivered strong results — total revenue of €247 million, YORVIPATH revenue of €197 million, and a non-IFRS operating profit of €55 million — along with the announcement of a $187.5 million Priority Review Voucher sale. Despite the positive numbers, shares drifted lower through late May and into early June, pressured by a broader biotech sell-off and lingering concerns about a top-line Q1 revenue miss versus consensus estimates.
The tide turned dramatically in the second half of June. Russell index reconstitution triggered heavy passive fund buying, while Ascendis' presentation of compelling five-year PaTH Forward data and continued commercial momentum for YUVIWEL — with more than 60 patient enrollments in the first weeks of its U.S. launch — reinforced institutional conviction. The rally carried shares from approximately $210 in early June to over $274 by July 2. However, the absence of fresh catalysts in July, combined with the typical post-reconstitution hangover and profit-taking, led to the subsequent pullback that defined the most recent 30-day period. The net result has been a quarter of high volatility but minimal net price change, reflecting a market that continues to reprice Ascendis' growth trajectory against near-term execution risks.
Trending AI Robots
For traders seeking to navigate volatile stocks like Ascendis Pharma with greater consistency, Tickeron's Trending AI Robots page offers a curated selection of AI-driven trading bots. Tickeron maintains hundreds of AI-powered bots that collectively trade across thousands of tickers, but only the top-performing and most relevant strategies are highlighted in this dynamically updated section. Each bot operates with distinct parameters — varying in strategy, trading timeframe, and risk profile — allowing users to identify approaches that align with their individual trading styles. Whether focused on short-term momentum plays or longer-duration trend-following, the Trending AI Robots section provides a window into which automated strategies are currently delivering results across real market conditions.
ASND Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several critical catalysts are poised to shape ASND's trajectory. First and foremost, the full Q2 2026 earnings release and management's forward guidance — including updates on YORVIPATH patient enrollment trends, YUVIWEL's commercial ramp, and progress toward the stated €500 million operating cash flow target for 2026 — will be closely scrutinized. Investors will also monitor the European Medicines Agency's decision on YUVIWEL, expected in Q4 2026, which would unlock a second major market for the achondroplasia therapy. Interim Week 78 data from the Phase 2 COACH trial combining TransCon CNP and TransCon hGH, anticipated later in 2026, could materially expand the addressable market. On the competitive front, ongoing developments from BioMarin in the achondroplasia space and any updates from AstraZeneca in hypoparathyroidism should be monitored. Macroeconomic conditions, healthcare policy developments, and the broader appetite for high-growth biotech will continue to influence near-term price action alongside company-specific fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ASND's Stochastic Oscillator entering overbought zone
The Stochastic Oscillator for ASND moved into overbought territory on August 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ASND as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASND declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ASND entered a downward trend on August 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ASND just turned positive on August 19, 2026. Looking at past instances where ASND's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .
ASND moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ASND advanced for three days, in of 268 cases, the price rose further within the following month. The odds of a continued upward trend are .
ASND may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ASND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.891) is normal, around the industry mean (20.145). P/E Ratio (19.395) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (13.106) is also within normal values, averaging (444.692).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drug candidates
Industry Biotechnology